Shot vs. IV: could a simple injection improve stomach cancer treatment?

NCT ID NCT07449780

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as an IV infusion. The goal is to see if the shot works as well and is safer. About 422 participants will take part, and the study has not started recruiting yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK104 (a type of immunotherapy) plus oxaliplatin and capecitabine chemotherapy
What this could lead to: If successful, this could offer a more convenient subcutaneous injection option for immunotherapy in advanced gastric cancer, potentially improving quality of life.
What could go wrong: This is an early-stage comparison of two delivery methods; it may not show a clear benefit in survival or tumor shrinkage. Side effects from immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.